If naftopidil had to be terminated during follow-up (for-cause termination), the reason was determined. In addition, the reasons for discontinuation of naftopidil and the need for subsequent retreatment after discontinuation were determined.Ībbreviations: IPSS, international prostate symptom scores QoL, quality of life BPI, BPH problem index BPH, benign prostatic hyperplasia s, second PVR, postvoid residual urine volume PV, prostate volume Q max, maximum flow rate.ĭiscontinuation was defined as the sum of for-cause termination and loss to follow-up. Thus, we conducted a prospective multicenter study to evaluate the long-term efficacy of naftopidil as well as to predict the risk factors for treatment failure. Some patients might need retreatment for recurrence of LUTS or the development of complications such as acute urinary retention (AUR) induced by BPH. In addition, although the tamsulosin study demonstrated that, aside from patients with treatment failure, >50% of patients quitted the medication for various reasons, including symptomatic improvement, 1 the clinical course after the discontinuation remained unknown. On the other hand, the long-term outcome of naftopidil, which has threefold higher affinity for α1D than for the α1A subtype, has never been prospectively investigated. 1 In that study, we found that 1) only a small portion of patients (approximately one-third) continued the same tamsulosin monotherapy for 5 years 2) there was a long-term efficacy of tamsulosin in patients who could continue the monotherapy and 3) a large prostate volume (PV) and a large amount of postvoid residual urine volume (PVR) at baseline were highly likely to result in the failure of the tamsulosin monotherapy. We previously reported the results of a 5-year prospective study of tamsulosin, which has threefold higher affinity for α1A than for the α1D subtype in patients with lower urinary tract symptoms (LUTS), suggestive of benign prostatic hyperplasia (BPH).
0 Comments
Leave a Reply. |